LähiTapiola Deploys Guidewire InsuranceSuite to Support Strategic Development
The LähiTapiola Group, Finnish mutual group of companies, and Guidewire Software, Inc. (NYSE:GWRE), provider of the industry platform general insurers rely upon, today announced that LähiTapiola is deploying Guidewire InsuranceSuite™. LähiTapiola is one of the leading Non-Life insurance companies in Finland. The InsuranceSuite implementation will support them in streamlining and rationalizing multiple, overlapping core systems as well as strengthening customer service and product delivery.
LähiTapiola is gradually replacing its current legacy systems in three phases. All Non-Life new business will be run on InsuranceSuite and existing business will be migrated, starting with its Private lines of insurance.
“Following an extensive vendor search LähiTapiola selected Guidewire based on their strong reputation and credibility, the usability of their software, and Proof of Concept results,” said Mikko Vastela, CIO, LähiTapiola. “As part of our strategic programme, and enabled through our InsuranceSuite deployment, we will have a renewed core system suite that can deliver a range of efficiencies and improvements in user experience both for internal and external users.”
Guidewire InsuranceSuite is enabling LähiTapiola to:
- Improve cost efficiency by harmonizing and automating operational processes;
- Provide new systems functionality through modern processes and interfaces; and
- Proactively deliver simpler, more flexible products to enhance customer service, and support increased acquisition and retention.
“With InsuranceSuite we will be able to provide an improved customer experience with more tailored products and services,” commented Christine Dahlman, Program Director, LähiTapiola. “We will also be better positioned to respond to developing insurance needs and generate a competitive advantage for our business.”
“We congratulate LähiTapiola on their initial deployment and look forward to continuing our work together,” said Sheridon Glenn, vice president, Field Consulting, EMEA, Guidewire Software. “The effort to transform their core systems and offer modern products and services to their customers is in keeping with their stated corporate goals. We are honoured to contribute to this endeavour.”
About Guidewire InsuranceSuite
Guidewire InsuranceSuite is a complete set of core systems and complementary modules combined to form the ideal technology platform that delivers on supporting your critical requirements, for all lines of business, while promoting sales, service, and underwriting excellence across your organization. Guidewire InsuranceSuite is a proven solution that has helped insurers worldwide significantly enrich customer and agent/broker relationships while simultaneously growing profitably and enabling agile responses to market threats and opportunities. InsuranceSuite provides a complete set of systems to support your core operations—underwriting, policy administration, billing, and claims management—to deliver the technology you need to successfully and continually advance your products, processes, and customer relationships. InsuranceSuite’s comprehensive components are built on a common platform, Guidewire InsurancePlatform™, that covers the entire insurance lifecycle while providing the deep functionality required for you to adapt and succeed in a time of rapid industry change.
About LähiTapiola
LocalTapiola Group is a mutual group of companies owned by its customers. LocalTapiola's mission is to safeguard its owner-customers' lives and success. Our vision is to offer Finnish people a safer and healthier life. The lifelong security concept means comprehensive and proactive services. LocalTapiola serves private customers, farmers, entrepreneurs, corporate customers, and organisations.
The number of owner-customers is approximately 1.6 million. The Group consists of 20 regional mutual insurance companies, as well as the national companies, LocalTapiola General, LocalTapiola Life, LocalTapiola Asset Management, and LocalTapiola Real Estate Asset Management. LocalTapiola employs approximately 3,400 people, half of whom work in the regional companies.
www.lahitapiola.fi/localtapiola
About Guidewire Software
Guidewire delivers the industry platform that general insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and ecosystem to enable our customers to run, differentiate, and grow their business. We are privileged to serve more than 350 general insurers in 32 countries. For more information, please visit https://www.guidewire.com. Follow us on twitter: @Guidewire_PandC.
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005229/en/
Contact information
LähiTapiola
Christine Dahlman, +358405073599
Program Director
christine.dahlman@lahitapiola.fi
or
onechocolate
Communications
Daniel Couzens, +44 (0)20 7437 0227
guidewire@onechocolatecomms.co.uk
or
Guidewire
Software (UK) Ltd
Louise Bradley, +44 (0)7474 837 860
lbradley@guidewire.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
